LGR5 and hepatocellular carcinoma: Interestingly, the highest 30% of LGR5 expressors fall into the non-proliferative class of HCC, characterized by activating mutations in β-catenin (or rarely, AXIN1) that display an immune desert phenotype [33, 78].